Di’ao Group Chengdu Pharmaceutical Co. Ltd. has synthesized glucagon-like peptide-1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of hypertension, diabetes type 1, cerebral infarction, metabolic dysfunction-associated steatohepatitis (MASH; NASH), metabolic syndrome, obesity, arteriosclerosis and Parkinson’s disease, among others.
Boomray Co. Ltd. has disclosed new conjugates comprising a fibroblast activation protein-α (FAPα) inhibitor covalently linked to radiolabeled chelating agents through a linker. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis, metabolic and neurological disorders.
Evopoint Biosciences Co. Ltd. has patented 2-acylglycerol O-acyltransferase 2 (MGAT2, MOGAT2) inhibitors. They are described as potentially useful for the treatment of obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, diabetes and arteriosclerosis.
Sunshine Lake Pharma Co. Ltd. has divulged heterocyclic fused ring compounds acting as pyruvate kinase PKLR activators potentially useful for the treatment of anemia, abetalipoproteinemia, hemolysis, hereditary spherocytosis, sickle cell disease and thalassemia.
Janssen Pharmaceutica NV has identified compounds targeting TAR DNA-binding protein 43 (TARDBP; TDP-43) acting as positron emission tomography (PET) imaging agents. They are designed for use in the diagnosis of neurological disorders.
Voltage-gated sodium channels, particularly Nav1.7, are highly expressed in peripheral sensory neurons and are crucial for pain signal conduction and signal transmission in the spinal dorsal horn. Because of their role in triggering pain, these channels are considered critical targets for analgesics. Systemic inhibition of Nav1.7 has been shown to abolish pain perception.
The serine/threonine kinase glycogen synthase kinase-3β (GSK-3β) plays a multifunctional role through its involvement in multiple signaling pathways. Because of its relevant role in Alzheimer’s disease (AD) pathogenesis, regulating GSK-3β activity has been proposed as a potential approach to target AD-related pathology.
Despite the successful application of adoptive T-cell transfer with chimeric antigen receptor (CAR)-engineered T cells for the treatment of various hematologic malignancies, several other hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), still lack effective treatment options.
Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) can cause severe and lethal bronchiolitis and pneumonia among particularly vulnerable populations, mostly infants, the elderly and immunocompromised patients. Researchers from Vanderbilt University Medical Center have isolated and characterized novel antibodies that cross-neutralize RSV and hMPV.
Tetrapharm (Tetra Pharm Technologies ApS) has announced promising preclinical data for TPC-026 for the chronic treatment and long-term management of metabolic disorders, including obesity. The preclinical findings support TPC-026 as a differentiated therapeutic candidate, designed to address underlying disease mechanisms, rather than symptoms alone.
RSS
